Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arena Pharmaceuticals (ARNA) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1769)	11/4/2010 5:24:52 PM
From: DewDiligence_on_SI	Respond to of 2274

Lief is good, but Teva’s Bill Marth holds that honor.

To: scaram(o)uche who wrote (1769)	11/9/2010 3:47:38 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2274

>> Moreover, Lief huffed and puffed back in 2007, when the R&D portion of the JNJ deal was canceled, about having rights returned and being able to find a new partner for next-generation GPR119 agonists. << While Lief HAS revisited his old B.S., fact is that B. Ingelheim recently paid (as noted in this thread) $10M upfront to NBIX..... Message 26723151 So, despite the stale huff and puff, I guess that it's possible that they could still double dip and find another partner?? Wonder what B.I. thinks of JNJ abandoning 597. As some will remember, 597 was the SECOND arena GPR119 agonist that was tested in the clinic by JNJ. After the first (668) failed, Lief made similar noises about how it worked to reduce increases in post-meal glucose, etc. Does anyone know that current status of PSN821 (or of DIVA, the PSN821 back-up).... osip.com And does anyone know the results/fallout from this trial??........ clinicaltrials.gov